Publication date: Jul 29, 2024
The emergency department (ED) is a vital source of healthcare for individuals living with sickle cell disease (SCD). Prior research indicates that during the COVID-19 pandemic some individuals with SCD avoided the ED for fear of acquiring COVID-19 or delayed visiting the ED by self-management of symptoms or pain crisis at home. The purpose of the current study was to understand ED utilization rates before and during the pandemic among individuals living with SCD. We conducted a retrospective cohort study using population-based SCD surveillance systems in California, Georgia, Michigan, and Tennessee to assess the impact of the pandemic on ED utilization among people with SCD by (1) analyzing trends in monthly ED utilization from January 2019 – December 2020, with specific attention given to immediate changes at the onset of the pandemic; and (2) calculating changes in the volume of utilization by comparing the total ED visits made from March – December 2020 to the same period in 2019, both overall and by demographic characteristics. Across all states, a decline in ED utilization during the onset of the pandemic was seen, with the largest decline seen in those under age 10. By December 2020, utilization rates were higher than their lowest observed month of April 2020, but had not fully returned to pre-COVID levels. During the pandemic, ED visits in each state decreased by as much as 25%, and the number of people with any ED utilization decreased by as much as 26%. This study confirms and extends the existing literature related to the impact of the pandemic on healthcare utilization patterns in the US, in a unique population with increased healthcare needs.
Open Access PDF
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | Emergency |
disease | MESH | COVID-19 pandemic |
disease | MESH | sickle cell disease |
disease | VO | population |
disease | VO | monthly |
disease | VO | volume |
disease | VO | USA |
disease | MESH | rare disease |
disease | MESH | complications |
disease | MESH | infection |
disease | MESH | stroke |
disease | VO | organ |
drug | DRUGBANK | Oxygen |
disease | IDO | blood |
disease | MESH | acute chest syndrome |
disease | MESH | death |
drug | DRUGBANK | Trestolone |
drug | DRUGBANK | Coenzyme M |
drug | DRUGBANK | Methionine |
drug | DRUGBANK | Pentaerythritol tetranitrate |
disease | VO | Optaflu |
drug | DRUGBANK | Ethionamide |
drug | DRUGBANK | Tretamine |
disease | VO | time |
drug | DRUGBANK | Fenamole |
disease | IDO | site |
disease | MESH | uncertainty |
disease | IDO | process |
disease | VO | vaccine |
disease | VO | ProHIBiT |
disease | VO | age |
disease | IDO | cell |
disease | MESH | anemia |
disease | MESH | Blood Cancer |
disease | MESH | myocardial infarction |
disease | MESH | heart failure |
disease | VO | unvaccinated |
disease | VO | vaccinated |